Centessa Pharmaceuticals (NASDAQ:CNTA) Releases Quarterly Earnings Results, Misses Estimates By $0.10 EPS

Key Points

• Centessa reported quarterly EPS of ($0.48), missing estimates by $0.10, yet the stock jumped to $39.72 on unusually heavy volume as investors priced in deal-related upside.
• Eli Lilly agreed to acquire Centessa for $38 per share in cash plus a contingent value right (CVR) worth up to $9, valuing the transaction at roughly $6.3B upfront and up to about $7.8B including milestones.
• Deal risks and governance concerns include recent shareholder litigation over price fairness and notable insider selling (about 349,073 shares worth ~$9.4M in three months); analysts maintain a consensus "Moderate Buy" with an average price target near $40.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) issued its earnings results on Tuesday. The company reported ($0.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.10), FiscalAI reports.

Centessa Pharmaceuticals Stock Performance

NASDAQ:CNTA traded up $12.14 during trading hours on Tuesday, reaching $39.72. 47,743,869 shares of the company's stock were exchanged, compared to its average volume of 1,505,304. Centessa Pharmaceuticals has a 1-year low of $9.60 and a 1-year high of $40.26. The company has a quick ratio of 10.57, a current ratio of 10.56 and a debt-to-equity ratio of 0.36. The firm has a market capitalization of $5.80 billion, a price-to-earnings ratio of -21.70 and a beta of 1.55. The company has a 50-day moving average of $26.29 and a 200 day moving average of $25.24.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on CNTA shares. Needham & Company LLC reissued a "hold" rating on shares of Centessa Pharmaceuticals in a research report on Tuesday. Weiss Ratings reiterated a "sell (d-)" rating on shares of Centessa Pharmaceuticals in a research report on Wednesday, January 21st. B. Riley Financial boosted their target price on Centessa Pharmaceuticals from $33.00 to $42.00 and gave the company a "buy" rating in a report on Monday, December 1st. Truist Financial upped their target price on Centessa Pharmaceuticals from $33.00 to $38.00 and gave the company a "buy" rating in a research report on Thursday, January 29th. Finally, Chardan Capital restated a "buy" rating and set a $30.00 price target on shares of Centessa Pharmaceuticals in a research note on Friday, January 2nd. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, Centessa Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average price target of $40.00.

Insider Activity

In other news, insider Iqbal J. Hussain sold 38,951 shares of the stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $25.15, for a total transaction of $979,617.65. Following the completion of the sale, the insider owned 57,645 shares in the company, valued at approximately $1,449,771.75. This represents a 40.32% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Karen M. Anderson sold 41,076 shares of the firm's stock in a transaction dated Thursday, March 26th. The stock was sold at an average price of $30.12, for a total value of $1,237,209.12. Following the transaction, the insider directly owned 62,085 shares in the company, valued at approximately $1,870,000.20. This represents a 39.82% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 349,073 shares of company stock valued at $9,429,412. Insiders own 7.09% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of CNTA. Fred Alger Management LLC lifted its holdings in shares of Centessa Pharmaceuticals by 53.8% during the third quarter. Fred Alger Management LLC now owns 190,360 shares of the company's stock worth $4,616,000 after purchasing an additional 66,604 shares during the period. Marshall Wace LLP grew its position in Centessa Pharmaceuticals by 152.4% in the 2nd quarter. Marshall Wace LLP now owns 343,318 shares of the company's stock valued at $4,511,000 after buying an additional 207,291 shares during the last quarter. The Manufacturers Life Insurance Company grew its position in Centessa Pharmaceuticals by 4.9% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 317,574 shares of the company's stock valued at $4,173,000 after buying an additional 14,928 shares during the last quarter. Deutsche Bank AG acquired a new position in Centessa Pharmaceuticals in the 4th quarter valued at $3,907,000. Finally, Squarepoint Ops LLC raised its position in Centessa Pharmaceuticals by 321.4% during the 4th quarter. Squarepoint Ops LLC now owns 81,812 shares of the company's stock worth $2,046,000 after buying an additional 62,399 shares during the last quarter. Institutional investors and hedge funds own 82.01% of the company's stock.

Key Centessa Pharmaceuticals News

Here are the key news stories impacting Centessa Pharmaceuticals this week:

• Positive Sentiment: Eli Lilly agreed to buy Centessa for $38 per share in cash plus a potential contingent value right (CVR) worth up to $9 per share, valuing the deal at roughly $6.3B up front and up to $7.8B including milestones; the transaction is framed as an expansion of Lilly’s neuroscience/sleep‑medicine pipeline. Eli Lilly to buy Centessa Pharma in $6.3 billion deal
• Positive Sentiment: Deal terms include the $38 cash upfront plus CVR milestones (up to $9) — investors are pricing some or all of the CVR into CNTA shares, which helps explain the stock trading above the $38 cash figure. Eli Lilly to acquire Centessa in $6.3B deal to expand neuroscience portfolio
• Positive Sentiment: Unusual options activity: large jump in call buying (nearly 3,000 calls traded, a ~472% spike vs. normal), signaling short‑term bullish speculation or hedging around the deal news.
• Neutral Sentiment: Analysts have mostly left ratings unchanged (Wolfe Research “peer perform”, Needham “hold”), suggesting the deal changes valuation more than near‑term fundamentals. Analyst coverage updates
• Neutral Sentiment: Trading metrics: unusually high share volume and CNTA trading near its 12‑month high, driven by the acquisition announcement and attendant positioning flows.
• Negative Sentiment: Shareholder litigation/investigations have been filed or announced (Ademi Firm and Halper Sadeh LLC) alleging Centessa shareholders may not be getting a fair price, which could lead to legal review, delay or pressure on deal terms. Shareholder Alert: The Ademi Firm investigates whether Centessa Pharmaceuticals plc is obtaining a Fair Price for Public Shareholders CNTA Stock Alert: Halper Sadeh LLC is Investigating Whether Centessa Pharmaceuticals plc is Obtaining a Fair Price for its Shareholders

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.